Test continuing somatostatin shots after tumor progression in GEP NET
Part of Cancer clinical trials.
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Sign consent and be well enough to do daily activities (ECOG 0–2)
- Have a confirmed diagnosis of non-functional, well-differentiated grade 1–2 GI/“GEP” neuroendocrine tumor
- Show imaging proof that your tumor grew while on first-line somatostatin shots at the labeled dose or higher
- Have not had prior everolimus, sunitinib, or PRRT (radiolabeled therapy)
- Be able to start either second-line targeted therapy (sunitinib or everolimus) or PRRT with 177Lu oxodotreotide, as decided by the study doctor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
This trial tests whether it's safe to stop somatostatin analogues (SSAs) after PRRT (a type of radiation therapy for neuroendocrine tumors). It is for people with midgut, hindgut, or pancreatic NETs that have not responded to SSAs and now need PRRT.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
Hear when a new Gastroenteropancreatic Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.